Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Viridian Therapeutics, Inc. (VRDN) reported a Q3 loss of $1.15 per share, slightly worse than the Zacks Consensus Estimate of a $1.11 loss. However, the company exceeded revenue expectations.
November 12, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Viridian Therapeutics reported a Q3 loss of $1.15 per share, missing the Zacks Consensus Estimate of $1.11. Despite the earnings miss, the company exceeded revenue expectations.
The earnings per share (EPS) miss is a negative indicator, but the fact that revenue exceeded expectations could offset some of the negative sentiment. This mixed result may lead to neutral short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100